September 1, 2026 — Jiangsu Xihong Biopharma Co., Ltd. (Xihong Biopharma) has announced that its Polycaprolactone (PCL) Microsphere Injectable Filler, marketed under the brand name 悦欢颜™, has received approval from the National Medical Products Administration (NMPA) of China as a Class III medical device.
NMPA Registration No.: 20263131843
This product is indicated for injection into the subcutaneous layer of the nasolabial fold area to correct moderate to severe nasolabial fold wrinkles.
Following the company’s previous approvals for Poly-L-Lactic Acid Microsphere Injectable Filler and Injectable Sodium Hyaluronate Composite Solution, 悦欢颜™ is the third product to receive NMPA Class III medical device registration in the field of regenerative biomaterials. This approval has further strengthened Xihong Biopharma’s regulatory and product foundation in China.
悦欢颜™ is formulated with polycaprolactone (PCL) microspheres as the core material, with sodium hyaluronate (HA) as the gel carrier, together with lidocaine.
PCL supports natural collagen regeneration and gradual remodeling, while HA facilitates smooth delivery and lidocaine helps reduce injection discomfort. Together, the formulation brings two defining benefits: regeneration and comfort.
The product reflects Xihong Biopharma’s focus on combining biomaterial science, formulation technology and application-driven product development.
Building on its regulatory foundation in China, the company is actively advancing its international development. Xihong Biopharma has submitted its CE certification application for its PLLA product and is progressing market entry initiatives in Brazil and Southeast Asia, with a focus on local regulatory pathways, market development.
“The NMPA Class III approval of 悦欢颜™ marks an important milestone in our commitment to advancing innovative injectable aesthetic solutions. With our portfolio spanning PCL, PLLA, CaHA and HA, we are building a broader platform to meet the evolving needs of aesthetic professionals and their patients. We look forward to bringing our biomaterial innovation and manufacturing capabilities to more international markets and working with trusted local partners to create long-term value for the global aesthetic medicine community.”said Mr. Zhang Tianming, General Manager of Xihong Biopharma.
Xihong Biopharma welcomes collaboration with experienced distributors, regulatory partners and aesthetic medicine companies that can contribute local expertise in registration, distribution and commercialization.
Jiangsu Xihong Biopharma Co., Ltd. specializes in the R&D, manufacturing and commercialization of regenerative biomaterials and injectable aesthetic products.
The company develops products across PCL, PLLA, CaHA ,PDRN,NCTF and HA platforms, with integrated capabilities covering R&D, manufacturing, quality management and regulatory development.
